Is Myrbetriq (mirabegron) contraindicated in patients with glaucoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 12, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is Myrbetriq Contraindicated for Glaucoma?

No, Myrbetriq (mirabegron) is not contraindicated in patients with glaucoma. Unlike anticholinergic medications used for overactive bladder, mirabegron is a beta-3 adrenergic agonist that does not affect pupil size or intraocular pressure and can be safely used in patients with either open-angle or angle-closure glaucoma 1, 2.

Mechanism and Safety Profile

  • Mirabegron works by stimulating beta-3 adrenergic receptors in the detrusor muscle of the bladder, causing relaxation and increased bladder capacity 1.
  • A randomized, double-masked, placebo-controlled study specifically evaluated ocular safety in 321 healthy volunteers receiving supratherapeutic doses of mirabegron 100 mg daily for 8 weeks 2.
  • The mean change in intraocular pressure from baseline to day 56 was -0.3 mmHg for mirabegron versus -0.2 mmHg for placebo, with a difference of only -0.1 mmHg (95% CI: -0.4 to 0.3) 2.
  • No treatment-emergent adverse events of glaucoma were reported, and no subjects discontinued due to increased intraocular pressure 2.
  • Mirabegron does not affect voiding urodynamic parameters, and the overall change in post-void residual is small 1.

Contrast with Anticholinergic Medications

  • Muscarinic receptor antagonists (antimuscarinics) used for overactive bladder are contraindicated in patients with narrow-angle glaucoma unless approved by the treating ophthalmologist 1.
  • Anticholinergics cause angle closure through pupillary dilation in patients with pre-existing anatomically narrow angles, bunching peripheral iris tissue into the angle 3, 4.
  • This mechanism is particularly dangerous in hyperopic, older phakic patients with shallow anterior chambers 3.
  • Several drug classes including anticholinergics, antihistamines, and antidepressants have been reported to induce or precipitate acute angle-closure glaucoma 4, 5.

Clinical Advantages of Mirabegron in Glaucoma Patients

  • Mirabegron is well tolerated in elderly patients and those with multiple comorbidities 1.
  • The most frequent adverse effects are hypertension, urinary tract infections, headache, and nasopharyngitis—not ocular complications 1.
  • The only cardiovascular contraindication is severe uncontrolled hypertension 1.
  • Mirabegron provides an important alternative for patients with overactive bladder who have glaucoma and cannot safely use anticholinergic medications 6.

Important Caveats

  • While mirabegron is safe for glaucoma patients, it is contraindicated in patients with severe uncontrolled hypertension 1.
  • Long-term data on efficacy and safety of mirabegron in men of any age with lower urinary tract symptoms are not yet available 1.
  • Clinicians should still monitor blood pressure regularly in patients taking mirabegron, as hypertension is a known adverse effect 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Randomized, double-masked, placebo-controlled study to assess the ocular safety of mirabegron in healthy volunteers.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2013

Guideline

Antihistamines and Topiramate-Induced Angle Closure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Drug-induced secondary glaucoma.

Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.